Skip to main content

Table 4 Factors associated with unsuccessful treatment outcomes among new pulmonary smear-positive tuberculosis patients registered during 2005–2013 in Anqing, China (n = 14,842)

From: Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study

Variables Total (n = 14,842) Unsuccessful (n = 739) Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Sex Female 3793 (25.56) 177 (4.67) 1    
Male 11,049 (74.44) 562 (5.09) 1.09 (0.92, 1.30) 0.30   
Age 15~ 24 1960 (13.21) 48 (2.45) 1   1  
25~ 34 1567 (10.56) 49 (3.13) 1.29 (0.86, 1.93) 0.22 1.31 (0.81, 2.11) 0.28
35~ 44 2412 (16.25) 87 (3.61) 1.49 (1.04, 2.13) 0.03 1.56 (1.00, 2.42) 0.049
45~ 54 2340 (15.77) 113 (4.83) 2.02 (1.43, 2.85) < 0.001 2.12 (1.38, 3.60) < 0.001
55~ 64 3269 (22.03) 182 (5.57) 2.35 (1.70, 3.24) < 0.001 2.32 (1.52, 3.53) < 0.001
≥65 3294 (22.19) 260 (7.89) 3.41 (2.50, 4.67) < 0.001 3.08 (2.03, 4.68) < 0.001
Ethnicity Han 14,819(99.85) 739 (4.99) 0.63   
Other 23 (0.15) 0 1    
Occupation Student 807 (5.44) 21 (2.60) 1    
Official staff 190 (1.28) 6 (3.16) 1.22 (0.49, 3.07) 0.67   
Service 277 (1.87) 9 (3.25) 1.26 (0.57, 2.78) 0.57   
Worker 1214 (8.18) 54 (4.45) 1.74 (1.04, 2.91) 0.03   
Farmer 11,567 (77.93) 618 (5.34) 2.11 (1.36, 3.28) < 0.001   
Retired staff 261 (1.76) 16 (6.13) 2.44 (1.26, 4.76) 0.009   
Unemployment 198 (1.33) 7 (3.54) 1.37 (0.58, 3.27) 0.48   
Other 328 (2.21) 8 (2.44) 0.94 (0.41, 2.13) 0.87   
Way of discovering patients Health examination 112 (0.75) 4 (3.57) 1    
Contact examination 12 (0.08) 1 (8.33) 2.46 (0.25, 23.94) 0.44   
Clinic visit due to symptoms 6716 (45.25) 294 (4.38) 1.24 (0.45, 3.38) 0.68   
Recommended due to symptoms 204 (1.37) 17 (8.33) 2.46 (0.81, 7.48) 0.11   
Referral 7137 (48.09) 370 (5.18) 1.48 (0.54, 4.03) 0.45   
Tracing 637 (4.29) 52 (8.16) 2.40 (0.85, 6.77) 0.10   
Other 24 (0.16) 1 (4.17) 1.17 (0.13, 11.00) 0.89   
Treatment management models Self-medication 8 (0.05) 6 (75.00)3 67.72(13.65, 336.07) < 0.001 70.38 (12.97, 381.85) < 0.001
Full-course supervision 14,512 (97.78) 615 (4.24) 1   1  
Full-course management 122 (0.82) 50 (40.98) 15.69(10.84, 22.71) < 0.001 16.45 (11.17, 24.22) < 0.001
Supervision in intensive phase 200 (1.35) 68 (34.00) 11.64(8.59, 15.77) < 0.001 10.86 (7.91, 14.91) < 0.001
X-Ray Normal 286 (1.93) 1 (0.35) 0.07(0.01, 0.47) 0.007 0.09 (0.01, 0.63) 0.016
Abnormal 14,447 (97.34) 726 (5.03) 1   1  
Unchecked 109 (0.73) 12 (11.01) 2.34(1.28, 4.28) 0.006 2. 70 (1.41, 5.16) 0.003
Cavity Yes 2527 (17.03) 154 (6.09) 1.30 (1.08, 1.56) 0.005 1.42 (1.18, 1.73) < 0.001
No 12,315 (82.97) 585 (4.75) 1   1  
Miliary Yes 99 (0.67) 14 (14.14) 3.18 (1.80, 5.63) < 0.001 3.39 (1.87, 6.13) < 0.001
No 14,743 (99.33) 725 (4.92) 1   1  
Regimen Regimen 1a 12,470 (84.02) 610 (4.89) 1    
Regimen 2b 2372 (15.98) 129 (5.44) 1.12 (0.92, 1.36) 0.26   
Total delay ≤17 3965 (26.71) 181 (4.56) 1    
17~ 33 3632 (24.47) 173 (4.76) 1.05 (0.85, 1.29) 0.68   
33~ 66 3594 (24.22) 164 (4.56) 1.00 (0.81, 1.24) > 0.99   
> 66 3651 (24.60) 221 (6.05) 1.35 (1.10, 1.65) 0.004   
  1. a2H3R3Z3E3/4H3R3. R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol. It means once-every-other-day HRZE for 2 months followed by 4 months of once-every-other-day HR
  2. b2HRZE/4HR. It means daily HRZE for 2 months followed by 4 months of daily HR